✦ LIBER ✦

Treatment of Dry Eye Syndrome with Orally Administered CF101: Data from a Phase 2 Clinical Trial

✍ Scribed by Isaac Avni; Hanna J. Garzozi; Irina S. Barequet; Fanni Segev; David Varssano; Gil Sartani; Noa Chetrit; Erez Bakshi; David Zadok; Oren Tomkins; Gilad Litvin; Kenneth A. Jacobson; Sari Fishman; Zivit Harpaz; Motti Farbstein; Sara Bar Yehuda; Michael H. Silverman; William D. Kerns; David R. Bristol; Ilan Cohn; Pnina Fishman

Book ID: 116805638
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 443 KB
Volume: 117
Category: Article
ISSN: 0161-6420
DOI: 10.1016/j.ophtha.2009.11.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of plaque-type psoriasis with

Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial

✍ M. David; L. Akerman; M. Ziv; M. Kadurina; D. Gospodinov; F. Pavlotsky; R. Yanko 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB

Efficacy and Safety of Diquafosol Ophtha

Efficacy and Safety of Diquafosol Ophthalmic Solution in Patients with Dry Eye Syndrome: A Japanese Phase 2 Clinical Trial

✍ Matsumoto, Yukihiro; Ohashi, Yuichi; Watanabe, Hitoshi; Tsubota, Kazuo 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 508 KB

Comparison of Orally Administered Cannab

Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group

✍ Strasser, F. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 303 KB

943e MuDelta Treatment Improves Bowel Mo

943e MuDelta Treatment Improves Bowel Movement Frequency and Urgency Episodes in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Results of a Phase 2 Clinical Trial

✍ P.S. Covington; D. Andrae; S. Dove; C.W. Randall; C.W. Randall; J. Davenport; G. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 52 KB

T1411 Predictors of Clinical Response fr

T1411 Predictors of Clinical Response from a Phase 2 Multi-Center Efficacy Trial Using Rifaximin, a Gut-Selective, Nonabsorbed Antibiotic for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome

✍ Ringel, Yehuda .; Zakko, Salam F.; Ferreira, Nelson L.; Bortey, Enoch; Wu, Tina; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

PRM90 Outcome Differences in Algorithms

PRM90 Outcome Differences in Algorithms Used for Indirect Mapping of Utility Values From HAQ-DI: An Assessment Based on Phase 2A Clinical Trial Data in Patients With Rheumatoid Arthritis After Treatment With NNC0109-0012 (Anti-II-20 MAB)

✍ Strandberg-Larsen, M.; Hansen, B.B.; Göthberg, M.; Valencia, X. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB